23 April 2009
Life after coronary stent thrombosis
David BeckerABCDEF, Pal Maurovich-HorvatABCDEF, Gyorgy BarcziBDEF, Gyorgy SzaboBDE, Gabor FulopBDE, Andrea NagyBCDE, Levente MolnarBDE, Astrid AporBDE, Eva BeliczaBCDE, Bela MerkelyABCDEGMed Sci Monit 2009; 15(5): CR236-241 :: ID: 869645
Abstract
Background
Coronary stent thrombosis is a catastrophic complication of percutaneous coronary intervention. There is a paucity of long-term data regarding the clinical outcome of patients who have suffered stent thrombosis.
Material and Method
We sought to assess the long-term clinical outcome of patients who suffered de novo ST-segment elevation myocardial infarction as well as those who suffered ST-segment elevation myocardial infarction as a result of stent thrombosis. In both patient groups, major cardiac adverse events were studied during a 1-year follow-up period.
Results
A total of 1890 consecutive patients who presented with ST-segment elevation myocardial infarction during the period January 2003 to December 2005 were studied: 1843 (97.5%) suffered de novo ST-segment elevation myocardial infarction, and 47 (2.5%) suffered ST-segment elevation myocardial infarction as a consequence of stent thrombosis. The rate of cardiogenic shock was significantly higher in the stent thrombosis group than in the de novo thrombosis group (21.3% vs 4.8%, respectively) (P<0.001). Mortality rates at 30 days (6.4% vs 8.8%) and at 1 year (17.0% vs 14.9%) showed no significant difference between the 2 groups. The repeat revascularization rate was higher among patients with post-stent thrombosis (35.7% vs 9.1%) (P<0.001), as was the major cardiovascular event rate (57.1% vs 31.2%) (P<0.001).
Conclusions
The long-term clinical outcome of patients who have suffered stent thrombosis is poor. Additional research is warranted to further improve therapeutic measures associated with stent thrombosis.
Keywords: Stents, Prospective Studies, Myocardial Infarction - surgery, Follow-Up Studies, Coronary Vessels - pathology, Aged, 80 and over, Thrombosis - pathology
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Preoperative Blood Transfusion Requirements for Hemorrhoidal Severe Anemia: A Retrospective Study of 128 Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943126
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952